摘要
目的探讨贝伐珠单抗联合TPLF方案治疗晚期胃癌的临床疗效及对患者外周血循环肿瘤细胞(CTCs)的影响。方法选取医院2015年6月至2018年6月收治的晚期胃癌患者104例,随机分为观察组和对照组,各52例。两组患者均采用TPLF方案化疗,观察组加用贝伐珠单抗。两组均以21 d为1周期,共治疗3个周期。结果观察组近期有效率为78.85%,明显高于对照组的57.69%(P<0.05);治疗3个周期后,两组患者血清癌胚抗原(CEA)和糖类抗原199(CA199)水平均明显降低,且观察组明显低于对照组(P<0.05);治疗后CTCs阳性率,观察组与治疗前比较无明显差异(P>0.05),对照组与治疗前比较明显升高(P<0.05),且观察组明显低于对照组(P<0.05);治疗期间,两组患者各类、各级不良反应发生率均相当(P>0.05)。结论贝伐珠单抗联合TPLF方案治疗晚期胃癌有一定近期疗效,并可降低CTCs阳性率。
Objective To investigate the clinical efficacy of bevacizumab combined with TPLF regimen in the treatment of advanced gastric cancer and its effect on peripheral blood circulating tumor cells(CTCs).Methods Totally 104 patients with advanced gastric cancer admitted to our hospital from June 2015 to June 2018 were selected and randomly divided into the observation group and the control group,52 cases in each group.The patients in the two groups were treated with TPLF chemotherapy regimen,on this basis,the patients in the observation group were treated with bevacizumab.Both groups were treated for 3 cycles with 21 d as one cycle.Results The short-term effective rate of the observation group was 78.85%,which was significantly higher than 57.69%of the control group(P<0.05).After 3 cycles of treatment,the levels of serum carcinoembryonic antigen(CEA)and glycoantigens 199(CA199)in the two groups were significantly decreased,and those in the observation group were lower than those in the control group(P<0.05).After treatment,the positive rate of CTCs in the observation group was not significantly different from that before treatment(P>0.05),while that in the control group was significantly increased(P<0.05),and that in the observation group was lower than that in the control group(P<0.05).During the treatment,the incidence of all kinds of adverse reactions in the two groups was similar(P>0.05).Conclusion Bevacizumab combined with TPLF regimen has short-term efficacy in the treatment of patients with advanced gastric cancer,which can reduce the positive rate of CTCs.
作者
李向荣
李萍
刘晓丽
LI Xiangrong;LI Ping;LIU Xiaoli(Department of Oncology,Xiaogan Central Hospital,Xiaogan,Hubei,China 432100)
出处
《中国药业》
CAS
2019年第22期38-40,共3页
China Pharmaceuticals
基金
湖北省卫生厅科研项目[WJ2017M239]
关键词
晚期胃癌
贝伐珠单抗
TPLF化疗方案
外周血循环肿瘤细胞
临床疗效
advanced gastric cancer
bevacizumab
TPLF chemotherapy regimen
peripheral blood circulating tumor cells
clinical efficacy
